June 1, 2025
Vascudyne Awarded Prestigious DoD Translational Research Grant to Advance Growing Heart Valve Technology
$4M Award from Congressionally Directed Medical Research Programs Will Support Clinical Translation of Breakthrough Tissue-Engineered Valved Conduits
Vascudyne announced it has been awarded a significant translational research grant from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to advance its revolutionary tissue-engineered heart valve technology toward clinical trials. The award, with Professor Robert Tranquillo at the University of Minnesota serving as Principal Investigator, supports the development of “off-the-shelf” valved conduits that address the critical unmet need for heart valves that can grow with children born with congenital heart disease.
The project directly tackles the harsh reality faced by families dealing with congenital heart defects like tetralogy of Fallot, where children currently require multiple open heart surgeries—typically 3 and sometimes as many as 5—because existing replacement valves do not grow with the child. Vascudyne’s innovative approach creates valved conduits from a unique collagenous matrix grown from donor skin cells, then decellularized to produce an “off-the-shelf” product that becomes populated with the recipient’s own cells after implantation, allowing the tissue to grow and self-repair. The technology also addresses the critical shortage of cadaver valves needed for the Ross procedure in young adults, where demand will soon exceed supply.
The grant will fund Good Manufacturing Process production of the tri-tube valve design, extensive functional and durability testing, and up to 18-month animal studies in both growing lambs and adult sheep to demonstrate growth capacity and long-term stability. Professor Tranquillo noted that “if a replacement valve could grow with the child, it could reduce the number of open heart surgeries required, perhaps to just one as an infant,” potentially transforming the treatment landscape for thousands of pediatric patients. The successful completion of this translational research program will position Vascudyne to request FDA approval for a Phase 1 clinical trial, marking a crucial step toward bringing this life-changing technology to patients who desperately need alternatives to current treatment options.
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
Copyright 2025 | Vascudyne, Inc.






















